Clinical Trials
Clinical trials are essential to developing new treatments for the diseases that cause dementia, and to ensuring that these are safe and effective.
For people in the UK to be among the first to benefit from new treatments the UK needs to be a leading location for clinical trials. This is dependent on a number of factors including investment in research and the clinical trials infrastructure and how easy it is for pharmaceutical companies to conduct trials and for new treatments to be approved for use in the healthcare system.
Alzheimer’s Research UK internal analysis, using data sourced from GlobalData Platform.
Alzheimer’s Research UK internal analysis, using data sourced from GlobalData Platform.
ARUK report: The Economic Value of Dementia Research.
UK’s Position in Global Dementia Trial Rankings
Alzheimer’s Research UK internal analysis; data sourced from the GlobalData Pharma Intelligence Platform.
The ribbon chart shows the number of Phase 1, 2 & 3 interventional drug trials for dementia initiated in each calendar year between 2015 and 2025.
This chart only shows the top six rankings for each year – so the chart can’t be used to assess the total number of dementia trials initiated in a given calendar year. Multinational trials will also be counted across multiple countries.
Where more than six countries are shown for a given year, this is due to multiple countries being tied for a certain ranking.
Number of participants recruited to NIHR phase 3 trials over 10 years
Parliamentary question for the Department of Health and Social Care.
